Today: 29 June 2026
Browse Category

NASDAQ:SLS 18 October 2025 - 26 June 2026

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Stock Jumps as One Trial Number Puts Cancer Readout in Focus

SELLAS Life Sciences shares rose 4.1% to $7.59 Tuesday after CEO Angelos Stergiou said its Phase 3 AML trial is two events from final analysis. The company reported $107.1 million in cash and a first-quarter net loss of $8.4 million. The REGAL trial’s main measure is overall survival. SELLAS remains blinded to results until the 80th event triggers data review.
20 May 2026
·
SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Life Sciences said its pivotal REGAL leukemia trial has recorded 78 of 80 events needed for final analysis, triggering a rise in after-hours trading. The company reported a first-quarter net loss of $8.4 million but ended March with $107.1 million in cash. Research and development spending increased to $5.1 million. SELLAS expects its cash to fund operations for at least 12 months.
13 May 2026
···
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences shares surged on heavy volume to $2.64 after the company presented updated Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2025. The study showed a 46% overall response rate among 35 patients, with no dose-limiting toxicities reported. Final analysis of the Phase 3 REGAL trial for galinpepimut-S is expected by year-end.
23 December 2025
·
SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (SLS) Stock on December 8, 2025: ASH 2025 Data, Cash Runway and Analyst Targets Over $6

SELLAS Life Sciences (NASDAQ: SLS) traded at $1.74 per share as of 09:13 UTC on December 8, 2025, following new Phase 2 data for its SLS009 drug in relapsed/refractory AML-MR. The study showed a 46% overall response rate in 35 patients, with no dose-limiting toxicities or treatment-related deaths reported. The company plans to expand trials to newly diagnosed high-risk AML in early 2026.
8 December 2025
··
Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences (SLS) Stock Skyrockets: BlackRock’s 5% Bet and Breakthrough Cancer Data Ignite Rally

Sellas Life Sciences shares closed at $2.14 on Oct. 17, up about 100% year-to-date, then surged another 38% after hours. BlackRock disclosed a 5.4% stake on Oct. 18, joining other major funds that increased holdings in Q2. Sellas’s lead AML drug passed a Phase 3 interim safety review, and its CDK9 inhibitor showed promising Phase 2 results. The company ended Q2 with $25 million cash and raised $23.6 million in September.
20 October 2025
··
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (NASDAQ:SLS) closed near $2.14 on Oct. 17, up about 100% year-to-date, with trading volatility and a 761% surge in call options on Oct. 14. Its GPS immunotherapy remains in Phase 3, while SLS009 showed strong preclinical results and a 44% response rate in Phase 2 AML data. Sellas raised $23.6M in September and had $25.3M cash at June 30. Analyst targets range from $6–7, with short interest at 18%.
18 October 2025
··
BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

BlackRock’s Big Bet Sends SELLAS Life Sciences (SLS) Stock Soaring – What’s Next for This Biotech?

SELLAS Life Sciences (NASDAQ: SLS) shares doubled year-to-date in 2025, closing at $2.14 on Oct. 17 after a 38% after-hours jump and hitting a 52-week high of $2.27. BlackRock disclosed a 5.4% stake in the company. Interim Phase 3 trial results for SELLAS’s lead cancer drug showed median survival over 13.5 months in AML patients. Final trial data is expected by year-end 2025.
18 October 2025

Stock Market Today

  • AI Infrastructure Boom Drives Surge in Stocks ALAB, VRT, CRWV Amid Data Center Spending
    June 28, 2026, 8:15 PM EDT. AI infrastructure spending is accelerating, highlighted by Nvidia's 92% year-over-year data center revenue rise. Beneficiaries include Astera Labs (NASDAQ: ALAB), with shares up 357% in a year as demand for high-speed networking grows, posting $308 million in Q1 revenue. CoreWeave (NASDAQ: CRWV) saw Q1 revenue double to $2.1 billion, backed by a $100 billion backlog, expanding AI-ready data centers rapidly. Vertiv Holding (NYSE: VRT) supplies power management and cooling systems to AI data centers, with 30% revenue growth in Q1 and $13.8 billion full-year revenue guidance. These companies are poised to capitalize on the investment cycle underpinning AI data center expansion, despite some risks such as customer concentration at CoreWeave.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop